How should a persistent cough be treated in a patient with cardiac amyloidosis?

Treatment of Persistent Cough in Cardiac Amyloidosis

Treat persistent cough in cardiac amyloidosis patients by systematically evaluating for the standard causes of chronic cough (GERD, upper airway cough syndrome, asthma) while being cautious with heart failure medications that may worsen symptoms, and screen for pulmonary amyloid involvement if the cough remains unexplained.

Initial Evaluation and Red Flag Assessment

First, determine if this represents a life-threatening condition. Screen for red flags that demand immediate attention 1:

• Hemoptysis - may indicate pulmonary amyloid involvement
• Prominent dyspnea at rest or night - common in cardiac amyloidosis with heart failure
• Peripheral edema with weight gain - suggests worsening heart failure
• Systemic symptoms (fever, weight loss) - could indicate pulmonary amyloidosis 2, 3
• Abnormal chest radiograph - essential to rule out pulmonary amyloid deposition

Medication Review

Immediately review and discontinue ACE inhibitors if present - these are a common cause of chronic cough and should be stopped for at least 4 weeks 1. This is particularly important because ACE inhibitors may not provide survival benefit in cardiac amyloidosis patients, especially those with ATTRv, and should be used cautiously 4. Consider switching to an angiotensin receptor blocker if renin-angiotensin system blockade is needed.

Check for sitagliptin use, which can also cause chronic cough 1.

Systematic Evaluation for Common Causes

Following the chronic cough algorithm, investigate the three most common causes 1:

1. Upper Airway Cough Syndrome (UACS)

• Trial of antihistamine/decongestant combination
• Assess response in 4-6 weeks

2. Gastroesophageal Reflux Disease (GERD)

• Critical point: Treatment should NOT be limited to acid suppression alone 1
• Include lifestyle modifications, dietary changes, and consider prokinetic agents
• Consider physiologic testing if refractory

3. Asthma/Cough-Variant Asthma

• Trial of inhaled corticosteroids with or without bronchodilators
• Consider leukotriene antagonists

Special Considerations in Cardiac Amyloidosis

Heart Failure Management Cautions

Be extremely cautious with standard heart failure medications that could worsen cough or be poorly tolerated 5:

• Avoid aggressive diuresis that might compromise already-reduced cardiac output
• Fludrocortisone and midodrine (used for orthostatic hypotension in amyloid neuropathy) may worsen heart failure and should be avoided or used very cautiously
• Beta-blockers should be used judiciously as they may not provide the same benefit as in other heart failure etiologies 4

Pulmonary Amyloidosis Consideration

If cough persists despite treating common causes, consider pulmonary amyloid involvement, particularly in AL amyloidosis 2, 3:

• Pulmonary amyloidosis can present with chronic cough as the primary symptom 3
• May involve interstitium, vessels, and airways 2
• Requires high-resolution CT chest and potentially lung biopsy for diagnosis
• Interstitial involvement is rare but indicates widespread disease and often concurrent cardiac involvement 3

Treatment Algorithm

1. Week 0: Discontinue ACE inhibitors and sitagliptin; screen for red flags
2. Week 0-4: Initiate empiric treatment for most likely cause based on history
3. Week 4-6: Reassess with validated cough severity tools; if partial response, maintain treatment and add therapy for second cause
4. Week 8+: If refractory, consider:
   • High-resolution CT chest to evaluate for pulmonary amyloidosis
   • Referral to specialized cough clinic
   • Bronchoscopy or lung biopsy if imaging suggests pulmonary involvement

Key Pitfalls to Avoid

• Do not assume cough is solely from heart failure - systematically evaluate other causes
• Do not continue ACE inhibitors - they cause cough and may not benefit these patients
• Do not overlook pulmonary amyloidosis - particularly in AL type with systemic symptoms
• Do not use medications for orthostatic hypotension (fludrocortisone, midodrine) without considering heart failure exacerbation risk 5
• Always maintain partially effective treatments when adding therapy for additional causes 1

Follow-up Strategy

• Routinely assess every 4-6 weeks with validated cough severity and quality of life tools 1
• Check medication compliance and assess barriers to treatment adherence
• Maintain all partially effective treatments as multiple causes may coexist
• Consider environmental and occupational factors at each visit 1